The Clinically Used Iron Chelator Deferasirox Is an Inhibitor of Epigenetic JumonjiC Domain-Containing Histone Demethylases

doi 10.1021/acschembio.9b00289.s001

Full Text

Abstract

Available in

Date

Unknown

Authors

Unknown

Publisher

American Chemical Society (ACS)

Related search

Deferasirox, an Oral Iron Chelator, Prevents Hepatocarcinogenesis and Adverse Effects of Sorafenib

Journal of Clinical Biochemistry and Nutrition

Clinical Biochemistry

English

In Vitro Enzyme Assays for JmjC-Domain-Containing Lysine Histone Demethylases (JmjC-KDMs)

Current Protocols in Pharmacology

Esperanto

Histone Deacetylation: IP4 Is an Epigenetic Coregulator

Nature Chemical Biology

Molecular Biology

English

Proteomic Profiling Reveals That Collismycin a Is an Iron Chelator

Scientific Reports

Multidisciplinary

English

Histone Demethylases in Cancer

Current Pharmacology Reports

English

Histone Lysine Demethylases inDrosophila Melanogaster

French

Histone Hypomethylation Is an Indicator of Epigenetic Plasticity in Quiescent Lymphocytes

Molecular Biology

English

Targeting Histone Demethylases in Cancer Therapy

Clinical Cancer Research

Cancer Research

English

Therapeutic Potentials of İnhibition Jumonji C Domain Containing Demethylases in Acute Myeloid Leukemia

Turkish Journal of Haematology

English